All In Biotech

Drug Trial Radar · NCT07009860

RESTORE TRIAL: Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)

RESTORE TRIAL: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)

Last checked: Nov 19, 2026Latest source record: Aug 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 121 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

121

Actual

Start

Jun 16, 2025

Primary completion

Sep 30, 2027

Study completion Sep 30, 2027

Sponsor

Lead sponsor
Altimmune, Inc.Industry
Sponsor type
Industry
First posted
Jun 8, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of pemvidutide in subjects with ALD.

Conditions

  • Alcohol-associated Liver Disease

Interventions

  • PemvidutideDrug

    Pemvidutide 2.4 mg SC Injection

  • PlaceboOther

    Placebo SC Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Relative (%) reduction in liver stiffness by VCTE compared to baselineTime frame: Week 48 and 24

Locations

37 sites in 2 countries. Site status is shown where the registry gives one.

  • Altimmune Clinical Study Site

    Peoria, Arizona

  • Altimmune Clinical Study Site

    Tucson, Arizona

  • Altimmune Clinical Study Site

    North Little Rock, Arkansas

  • Altimmune Clinical Study Site

    Fresno, California

  • Altimmune Clinical Study Site

    La Jolla, California

  • Altimmune Clinical Study Site

    Pasadena, California

  • Altimmune Clinical Study Site

    Bradenton, Florida

  • Altimmune Clinical Study Site

    Doral, Florida

  • Altimmune Clinical Study Site

    Fort Myers, Florida

  • Altimmune Clinical Study Site

    Miami, Florida

  • Altimmune Clinical Study Site

    Miami, Florida

  • Altimmune Clinical Study Site

    Miami Lakes, Florida

  • Altimmune Clinical Study Site

    Naples, Florida

  • Altimmune Clinical Study Site

    Orlando, Florida

  • Altimmune Clinical Study Site

    Atlanta, Georgia

  • Altimmune Clinical Study Site

    Indianapolis, Indiana

  • Altimmune Clinical Study Site

    Louisville, Kentucky

  • Altimmune Clinical Study Site

    Bastrop, Louisiana

  • Altimmune Clinical Study Site

    Marrero, Louisiana

  • Altimmune Clinical Study Site

    West Monroe, Louisiana

  • Altimmune Clinical Study Site

    St Louis, Missouri

  • Altimmune Clinical Study Site

    Las Vegas, Nevada

  • Altimmune Clinical Study Site

    Manhasset, New York

  • Altimmune Clinical Study Site

    New York, New York

  • Altimmune Clinical Study Site

    Syracuse, New York

  • Altimmune Clinical Study Site

    Wilmington, North Carolina

  • Altimmune Clinical Study Site

    Westlake, Ohio

  • Altimmune Clinical Study Site

    Brownsville, Texas

  • Altimmune Clinical Study Site

    Dallas, Texas

  • Altimmune Clinical Study Site

    Edinburg, Texas

  • Altimmune Clinical Study Site

    Houston, Texas

  • Altimmune Clinical Study Site

    Houston, Texas

  • Altimmune Clinical Study Site

    San Antonio, Texas

  • Altimmune Clinical Study Site

    San Antonio, Texas

  • Altimmune Clinical Study Site

    Waco, Texas

  • Altimmune Clinical Study Site

    Seattle, Washington

  • Altimmune Clinical Study Site

    San Juan, Puerto Rico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.